Wall Street analysts expect BioScrip Inc (NASDAQ:BIOS) to post sales of $177.51 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for BioScrip’s earnings, with estimates ranging from $177.01 million to $178.00 million. BioScrip reported sales of $168.58 million in the same quarter last year, which suggests a positive year over year growth rate of 5.3%. The business is expected to issue its next quarterly earnings results on Thursday, May 9th.
According to Zacks, analysts expect that BioScrip will report full year sales of $754.46 million for the current financial year, with estimates ranging from $750.72 million to $761.65 million. For the next year, analysts forecast that the business will post sales of $800.52 million, with estimates ranging from $794.00 million to $807.03 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for BioScrip.
BioScrip (NASDAQ:BIOS) last released its earnings results on Friday, March 15th. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.11). The firm had revenue of $183.57 million during the quarter, compared to the consensus estimate of $188.39 million. The company’s revenue was up .5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.03) EPS.
Shares of BioScrip stock traded up $0.09 on Friday, hitting $1.99. 74,295 shares of the company’s stock traded hands, compared to its average volume of 2,274,539. The stock has a market cap of $243.49 million, a P/E ratio of -4.06 and a beta of 0.76. BioScrip has a 52-week low of $1.86 and a 52-week high of $4.14.
A number of institutional investors have recently bought and sold shares of BIOS. Vanguard Group Inc. increased its holdings in shares of BioScrip by 0.5% in the third quarter. Vanguard Group Inc. now owns 5,987,679 shares of the company’s stock worth $18,562,000 after purchasing an additional 27,904 shares during the period. Tibra Equities Europe Ltd bought a new position in shares of BioScrip during the 4th quarter worth approximately $503,000. Caxton Associates LP bought a new position in shares of BioScrip during the 4th quarter worth approximately $52,000. Royce & Associates LP raised its stake in shares of BioScrip by 3.6% during the 3rd quarter. Royce & Associates LP now owns 2,204,000 shares of the company’s stock worth $6,832,000 after acquiring an additional 77,000 shares in the last quarter. Finally, BlackRock Inc. raised its stake in shares of BioScrip by 0.4% during the 3rd quarter. BlackRock Inc. now owns 7,616,244 shares of the company’s stock worth $23,610,000 after acquiring an additional 31,899 shares in the last quarter. Institutional investors and hedge funds own 82.51% of the company’s stock.
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
Featured Article: How Do Mutual Funds Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.